An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.

See ANZCTR for full trial details >

 

Trial Summary:

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.

Supported By:

Cancer Australia, UCL Cancer Trials Centre, Astra Zeneca

Eligibility:

Histologically proven diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after day 1 of the last cycle of first-line platinum-based chemotherapy and requiring treatment with second-line platinum-based chemotherapy

Registration ID:

NCT03278717

Participation:

Australia, UK

Australian Lead Group:

ANZGOG

Status:

Recruiting

Activation Date:

12.11.2018

Chairs:

A/Prof Linda Mileshkin

Contact:

icon9.study@sydney.edu.au